Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Key Highlights
- ➤Alkermes will present two oral sessions and six posters at Sleep Europe 2026
- ➤REVITALYZ phase 3 positive topline results will receive detailed presentation in idiopathic hypersomnia
- ➤Alixorexton extension data will assess safety and durability through approximately nine months
- ➤Alixorexton phase 3 Brilliance studies are evaluating narcolepsy types 1 and 2
- ➤LUMRYZ cannot be marketed for idiopathic hypersomnia before March 1, 2028
Expert Statements
Giuseppe Plazzi, Neurologist, Director of the Narcolepsy Center at the IRCCS of the Neurological Sciences of Bologna and Professor of Childhood Neuropsychiatry at the University of Modena and Reggio Emilia
“I am pleased to present results from the Vibrance-1 phase 2 study and long-term extension evaluating alixorexton in patients with narcolepsy type 1 and type 2 at Sleep Europe. Together, these results further characterize the potential of alixorexton in narcolepsy and provide evidence supporting sustained clinical benefit with longer-term treatment”
Richard Bogan, Principal of Bogan Sleep Consultants, LLC and Associate Clinical Professor at the University of South Carolina School of Medicine
“I am honored to present results from the REVITALYZ phase 3 trial evaluating LUMRYZ in adults with idiopathic hypersomnia, a chronic neurological disorder for which there are limited treatment options. It is an exciting time in sleep medicine, and the research being presented at Sleep Europe 2026 underscores the significant scientific progress we are seeing across narcolepsy and idiopathic hypersomnia”
Craig Hopkinson, Chief Medical Officer and Executive Vice President, Research & Development at Alkermes
“The breadth of data being presented by Alkermes at Sleep Europe 2026 reflects both the strength of our research programs and our leadership in the field of sleep medicine. We look forward to sharing detailed findings from the REVITALYZ phase 3 study of LUMRYZ in patients with idiopathic hypersomnia, as well as initial data from our long-term extension study evaluating the durability of effect of alixorexton in patients with narcolepsy type 1 and type 2”
Craig Hopkinson, Chief Medical Officer and Executive Vice President, Research & Development at Alkermes
“Through our ongoing investment in scientific innovation across narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, we aim to help advance differentiated treatment approaches and address the diverse needs of people living with these serious neurological conditions.”
Alkermes to Present New Data on Alixorexton and LUMRYZ(®) (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral Presentation —
Get started
Create a free account to read the full story.